Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plc

Investec Bank, acting as adviser and joint broker to Advanced Medical Solutions Group, disclosed client-serving dealings on 18 September 2026 under UK Takeover Code Rule 8.5. The bank purchased 35,703 ordinary shares at 281.5p-282p and sold 515,471 shares at the same price range, for a net sale of 479,768 shares. The filing reported no derivative transactions, indemnities, options, or other dealing arrangements.

Analysis

This is not an insider-signal or a proprietary positioning signal for INVP. Recognised intermediary activity is typically client facilitation and inventory management under the Takeover Code; the apparent net share flow should not be read as Investec expressing a view on Advanced Medical Solutions (AMS.L) deal completion, offer value, or downside risk. The narrow execution range instead suggests liquidity was available around that level, not that it constitutes a fundamental support or clearing price.

For AMS.L, the relevant 1-3 month catalysts are formal offer documentation, any revision to consideration, stated acceptance conditions, regulatory timetable, and disclosure of irrevocables—not daily Rule 8.5 broker dealing. A failure to progress to a firm offer or an extension in regulatory timing would reopen standalone valuation risk and likely widen the implied deal spread. Over 6-18 months, any strategic premium should be judged against AMS.L's standalone growth and margin trajectory; this filing provides no evidence on either.

The contrarian point is that repeated intermediary disclosures can create a false impression of informed selling near a bid. In cash-deal situations, that flow is more often arbitrage/client turnover, while the economically meaningful signal is the spread between the trading price and confirmed consideration after adjusting for timing and break risk. Without the offer price, conditions, and current spread, there is no defensible expected-value trade from this disclosure alone.

Key Decisions for Investors

• No directional position in INVP from this filing; treat it as compliance-driven client-serving activity rather than a catalyst for Investec earnings or valuation.
• For any existing AMS.L merger-arbitrage position, maintain only after calculating annualized spread return using confirmed consideration, expected closing date, financing certainty, and regulatory/acceptance conditions; do not use the 281.5-282p dealing range as a stop-loss or valuation anchor.
• Set alerts for a Rule 2.7 firm-offer announcement, acceptance-threshold disclosures, Competition and Markets Authority developments, or an offer withdrawal/extension. A deteriorating probability of completion or spread widening without new terms is the key risk signal, not subsequent Rule 8.5 prints.
• If AMS.L trades materially below confirmed cash consideration and the annualized gross spread exceeds the fund's required return after a conservative break-price assumption, consider a small long AMS.L position; otherwise remain flat pending missing offer-term data.